Summary
Natera Inc (Natera) develops genetic and cell-free deoxyribonucleic acid (cfDNA) testing solutions. The company’s products include Signatera, a personalized ctDNA (circulating tumor DNA) blood test to assess MRD (molecular residual disease) and its recurrence; Aletra, a tissue-based genomic profiling test to identify genomic alterations and oncology biomarkers in a tumor; Prospera, a transplant rejection test to evaluate the risk of rejection of a transplanted kidney. It also offers a Renasight test to detect the genetic causes of kidney diseases, Horizon carrier screening test, Panorama non-invasive prenatal screening test, Empower hereditary cancer test, Vistara prenatal single gene screening test, Anora miscarriage test and Spectrum preimplantation genetic test. Natera is headquartered in Austin, Texas, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook